Organization Description
Senolytic Therapeutics (STX) was developing proprietary strategies to destroy the senescent cells that generate the senescence-associated secretory phenotype (SASP) and harm tissues, thus treating one of the hallmarks of aging and associated age-related diseases.
At its founding, STX had three core programs. One, with lead senolytic compound SEN01, was intended to target certain cancers, as well as fibrotic diseases — specifically idiopathic pulmonary fibrosis (IPF), a terrible disease of aging characterized by lung scarring and a high burden of senescent cells. A second program, in the discovery phase, was focused on enhancing or reinforcing the immune clearance of senescent cells, with cancer as the intended indication. And a third “discovery platform to design novel molecules and tested in other anti-aging indications in-house or in collaboration with academic institutions.”
The company was cofounded by Dr. Miguel Serrano and Dr. Marc Ramis Castelltort, had offices in Barcelona, Spain, and Boston, Massachusetts, and was a member of the Life Biosciences (LB) group, which then owned multiple rejuvenation biotechnology companies, each focusing on a different hallmark of aging. However, its website has been defunct since late 2021, STX is not listed on LB’s website as of August 2025, and there are no senolytic compounds in LB’s current pipeline chart. Its intellectual property was outlicensed to Rejuversen in 2021